GLPwatch

Optimizing weight control in diabetes: antidiabetic drug selection.

Diabetes Metab Syndr Obes · 2010

Last updated 2026-05-28

Metformin may help with weight loss or reduce weight gain when used alone or with other drugs. GLP-1 drugs like liraglutide and exenatide are linked to weight loss, while pioglitazone and rosiglitazone may cause weight gain. DPP-4 inhibitors are considered weight-neutral, and insulin detemir may help with weight control alongside blood sugar control.

AI summary of the abstract below.

JournalDiabetes Metab Syndr Obes, 2010
Citations5
Relative citation ratio0.13
NIH percentile9
Molecules
Conditions studied Type 2 Diabetes, Obesity

Abstract

CLINICAL QUESTION: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes? RESULTS: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control. IMPLEMENTATION: Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.1Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs.

Verbatim abstract via PubMed 21437098 ↗